NovaBridge Biosciences (NBP) Total Liabilities (2017 - 2025)

NovaBridge Biosciences (NBP) has 9 years of Total Liabilities data on file, last reported at $29.6 million in Q4 2025.

• Quarterly Total Liabilities rose 156.78% year-over-year to $29.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.6 million (up 156.78% YoY) and the FY2025 annual result came in at $29.6 million, up 156.78% from the prior year.
• Total Liabilities advanced to $29.6 million in Q4 2025 per NBP's latest filing, from $18.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $163.6 million in Q4 2022 and bottomed at $10.0 million in Q2 2025.
• The 5-year median for Total Liabilities is $29.6 million (2025), against an average of $74.0 million.
• The widest annual swing landed in 2024, when Total Liabilities plunged 90.73%; it then soared 156.78% in 2025.
• Tracing NBP's Total Liabilities over 5 years: stood at $162.9 million in 2021, then grew by 0.43% to $163.6 million in 2022, then decreased by 24.05% to $124.3 million in 2023, then plunged by 90.73% to $11.5 million in 2024, then surged by 156.78% to $29.6 million in 2025.
• Per Business Quant, the three latest NBP Total Liabilities figures stand at $29.6 million (Q4 2025), $18.5 million (Q3 2025), and $10.0 million (Q2 2025).

Peer Comparison